George Mason University's CAP-CLIA Laboratory Utilizes Aushon Biosystems's Array Technology for Individualized and Targeted Treatment for Cancer Patients

BURLINGTON, Mass.--(BUSINESS WIRE)--In a cooperative effort to promote the development of personalized medicine based on reverse-phase protein array technology, Aushon BioSystems has placed a 2470 Arrayer in a CAP-CLIA laboratory established by George Mason University. Mason’s CAP-CLIA laboratory, under the direction of Profs. Lance Liotta and Emanuel Petricoin, is focused on trials of clinical cancer treatments based on an individual’s unique protein expression profile. The new 2470 Arrayer joins several other 2470s in service at Mason.